Prostate Cancer: A Contemporary Approach to Treatment and Outcomes.
Prostate Cancer: A Contemporary Approach to Treatment and Outcomes. Med Clin North Am. 2018 Mar;102(2):215-229 Authors: Weiner AB, Kundu SD Abstract Given the high incidence of prostate cancer and the need for shared decision-making before screening, it is imperative that primary care providers understand treatment options and treatment adverse effects. In this review article, the treatment options for the localized and metastatic prostate cancer are discussed, including the different modalities and their indications, adverse effects, oncologic outcomes, posttreatment monitoring, and potential treatment options following cancer recurrence. PMID: 29406054 [PubMed - in process]
Conclusions: The use of a hydrogel prior to salvage HDR-BT in a patient previously treated with HDR-BT is feasible and could help reduce the rectal exposure in the salvage setting. PMID: 29789766 [PubMed]
Conclusions: LDR brachytherapy is an effective treatment option in low- to intermediate-risk prostate cancer patients. We observed low biochemical relapse rates and minimal GU toxicities several years after treatment in patients with or without TURP. However, a small risk of urinary retention was observed in some patients. PMID: 29789764 [PubMed]
AbstractPurposeProstate cancer (PCa) is the second leading cause of cancer death in U.S. men [American Cancer Society (ACS)], most often affecting men age 50 and older. The study provides information about factors that influence rural AA men in their decision to undergo screening for PCa with a specific focus on PCa knowledge among AA men and their health care advocates.MethodsA longitudinal quantitative study included AA males and their health care advocates. Participants were from three Alabama rural counties. Measures included demographics, PCa knowledge, decisional conflict, and health literacy scales.ResultsThirty-thr...
AbstractPurpose of reviewThe introduction of antiretroviral therapy (ART) has revolutionized HIV infection management, resulting in improved outcomes and survival for people living with HIV (PLWH). However, as PLWH are living longer and aging, non-AIDS-defining cancers (NADCs) represent a significant source of morbidity and mortality in the HIV-infected population. Here, we review the epidemiology of NADCs in PLWH.Recent findingsCancer mortality among PLWH is much higher than that among the general population. Up to 10% of deaths among PLWH have been attributed to NADCs. Furthermore, PLWH have an increased risk for specifi...
Correct answer: D. The UK National Screening Committee of Public Health England (PHE) (https://www.gov.uk/guidance/prostate-cancer-risk-management-programme-overview) does not recommend routine screening (A, B) but the scenario is a broader one than this patient and is best dealt with by the local director of public health who is responsible for the impl ementation of national programmes locally (D). This is preferable to C. Reassurance and explanation (E) is appropriate for the individual but not for this situation.
Conclusion Competing risk models, but not Cox models, demonstrated temporal increases in SPC-specific mortality. Greater detection of non-fatal first prostate cancers appears to have contributed to this trend.
Condition: High Risk Prostate Cancer Interventions: Diagnostic Test: Whole body contrast enhanced computer tomography; Diagnostic Test: 99mTC-HMDP planar bone scintigraphy (BS); Diagnostic Test: 99mTc-HMDP single photon emission computer tomography/computer tomography; Diagnostic Test: Whole-body magnetic resonance imaging; Diagnostic Test: Fluorine-18-prostate specific membrane antigen-1007- positron emission tomography/computer tomography Sponsors: Turku University Hospital; University of Turku Active, not recruiting
CONCLUSIONS: Afro-Caribbean populations in French West Indies share the same major clinical and pathological risk factors of BCR after RP identified in other ethnic groups. Perioperative blood loss appears to be an additional and independent predictive factor of BCR. LEVEL OF PROOF: 4. PMID: 29789237 [PubMed - as supplied by publisher]
CONCLUSION: A reduction of LUTS is observed in patients with locally advanced or metastatic prostate cancer treated with triptorelin in routine practice. This is in agreement with similar observational studies of triptorelin conducted in other countries. LEVEL OF PROOF: 4. PMID: 29789236 [PubMed - as supplied by publisher]
CONCLUSION: Mp-MRI is a useful exam for selecting patients eligible for AS even if the situation remains unclear after prostate biopsies including targeted biopsies. Upon confirmation by further studies, mp-MRI should be considered as an independent criterion before entering an AS program. LEVEL OF EVIDENCE: 4. PMID: 29789235 [PubMed - as supplied by publisher]